Photodynamic therapy of a 2-methoxyestradiol tumor-targeting drug delivery system mediated by Asn-Gly-Arg in breast cancer

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1551-1562

  Shi, Jinjin ^a   Wang, Zhenzhen ^a   Wang, Lei ^a   Wang, Honghong ^a   Li, Lulu ^a   Yu, Xiaoyuan ^a   Zhang, Jing ^a   Ma, Rou ^a   Zhang, Zhenzhong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Drug delivery system; Fullerene; Photodynamic therapy; Tumor targeting

Indexed keywords

2 ETHOXYESTRADIOL; AMINO ACID DERIVATIVE; ASPARAGYLGLYCYLARGININE; CELL DNA; ESTRADIOL DERIVATIVE; FULLERENE; MALONIC ACID; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL MEMBRANE TRANSPORT; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; HUMAN; HUMAN CELL; ILLUMINATION; IRRADIATION; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION;

DRUG DELIVERY SYSTEM; FULLERENE; PHOTODYNAMIC THERAPY; TUMOR TARGETING;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DNA FRAGMENTATION; DRUG CARRIERS; ESTRADIOL; FEMALE; FULLERENES; HUMANS; MALONATES; MCF-7 CELLS; MICE; OLIGOPEPTIDES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; REACTIVE OXYGEN SPECIES;

EID: 84876499061     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40011     Document Type: Article

References (42)

1. Isakovic A, Markovic Z, Todorovic-Markovic B, et al. Distinct cytotoxic mechanisms of pristine versus hydroxylated fullerene. Toxicol Sci. 2006;91:173-183.
2. Pinteala M, Dascalu A, Ungurenasu C. Binding fullerenol C(60)(OH) (24) to dsDNA. Int J Nanomedicine. 2009;4:193-199.
3. Sitharaman B, Zakharian TY, Saraf A, et al. Water-soluble fullerene (C60) derivatives as nonviral gene-delivery vectors. Mol Pharm. 2008;5:567-578.
4. Yudoh K, Karasawa R, Masuko K, Kato T. Water-soluble fullerene (C60) inhibits the osteoclast differentiation and bone destruction in arthritis. Int J Nanomedicine. 2009;4:233-239.
5. Yamago S, Tokuyama H, Nakamura E, et al. In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. Chem Biol. 1995;2:385-389.
6. Kang B, Yu D, Dai Y, Chang S, Chen D, Ding Y. Cancer-cell targeting and photoacoustic therapy using carbon nanotubes as "bomb" agents. Small. 2009;5:1292-1301.
7. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem. 2006;97:1184-1190.
8. Subramani K, Hosseinkhani H, Khraisat A, Hosseinkhani M, Pathak Y. Targeting nanoparticles as drug delivery systems for cancer treatment. Current Nanoscience. 2009;5:135-140.
9. Partha R, Mitchell LR, Lyon JL, Joshi PP, Conyers JL. Buckysomes: fullerene-based nanocarriers for hydrophobic molecule delivery. ACS Nano. 2008;2:1950-1958.
10. Henderson BW, Gollnick SO, Snyder JW, et al. Choice of oxygenconserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res. 2004;64:2120-2126.
11. Triesscheijn M, Baas P, Schellens JH, Stewart FA. Photodynamic therapy in oncology. Oncologist. 2006;11:1034-1044.
12. Akiyama M, Ikeda A, Shintani T Y. et al. Solubilisation of [60]fullerenes using block copolymers and evaluation of their photodynamic activities. Org Biomol Chem. 2008;6:1015-1019.
13. Isakovic A, Markovic Z, Nikolic N, et al. Inactivation of nanocrystalline C60 cytotoxicity by gamma-irradiation. Biomaterials. 2006;27: 5049-5058.
14. Yang X, Chen L, Qiao X, Fan C. Photo-induced damages of cytoplasmic and mitochondrial membranes by a [C60]fullerene malonic acid derivative. Int J Toxicol. 2007;26:197-201.
15. Reid PE, Brown NJ, Holen I. Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. Mol Cancer. 2009;8:49.
16. Baar J, Silverman P, Lyons J, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res. 2009;15:3583-3590.
17. Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60:722-727.
18. Oostendorp M, Douma K, Hackeng TM, van Zandvoort MA, Post MJ, Backes WH. Pharmacokinetics of contrast agents targeted to the tumor vasculature in molecular magnetic resonance imaging. Contrast Media and Molecular Imaging. 2010;5:9-17.
19. Luan Y, Xu W. The structure and main functions of aminopeptidase N. Curr Med Chem. 2007;14:639-647.
20. Zhang Z, Wang B, Li H, Zhou T, Zhang L. The inhibitory effects of nanosize delivery system for antisense oligonucleotide of hTERT on EC9706 cells. Cancer Biol Ther. 2007;6:329-334.
21. Colombo G, Curnis F, De Mori GM, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem. 2002;277:47891-47897.
22. Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63:7400-7409.
23. Garde SV, Forte AJ, Ge M, et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anti-Cancer Drug. 2007;18:1189-1200.
24. Sutherland TE, Anderson RL, Hughes RA, et al. 2-Methoxyestradiol - a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discov Today. 2007;12:577-584.
25. Newman SP, Leese MP, Purohit A, et al. Inhibition of in vitro angiogenesis by 2-methoxy-and 2-ethyl-estrogen sulfamates. Int J Cancer. 2004;109:533-540.
26. Funakoshi T, Birsner AE, D'Amato RJ. Antiangiogenic effect of oral 2-methoxyestradiol on choroidal neovascularization in mice. Exp Eye Res. 2006;83:1102-1107.
27. Ireson CR, Chander SK, Purohit A, et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer. 2004;90:932-937.
28. Nair SK, Verma A, Thomas TJ, et al. Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Lett. 2007;250:311-322.
29. Van Zijl C, Lottering ML, Steffens F, Joubert A. In vitro effects of 2-methoxyestradiol on MCF-12A and MCF-7 cell growth, morphology and mitotic spindle formation. Cell Biochem Funct. 2008;26: 632-642.
30. Gong QF, Liu EH, Xin R, Huang XN, Gao N. 2ME and 2OHE2 exhibit growth inhibitory effects and cell cycle arrest at G2/M in RL95-2 human endometrial cancer cells through activation of p53 and Chk1. Mol Cell Biochem. 2011;352:221-230.
31. Pribluda VS, Gubish ER Jr, Lavallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev. 2000;19: 173-179.
32. Ireson CR, Chander SK, Purohit A, et al. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Brit J Cancer. 2004;90:932-937.
33. Cheng F, Yang X, Zhu H, Sun J, Liu Y. Synthesis of oligoadducts of malonic acid C60 and their scavenging effects on hydroxyl radical. J Phys Chem Solids. 2000;61:1145-1148.
34. Wang L, Zhang M, Zhang N, et al. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomedicine. 2011;6:2641-2652.
35. Ray A, Santhosh K, Chattopadhyay S, Samanta A, Bhattacharya S. Spectroscopic and theoretical investigations on effective and selective interaction of fullerenes C60 and C70 with a derivatized Zn-phthalocyanine: stabilization of charge-recombined state by side-on approach of C70. J Phys Chem A. 2010;114:5544-5550.
36. Wang L, Zhang M, Zhang N, et al. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomedicine. 2011;6:2641-2652.
37. Liu Z, Sun X, Nakayama-Ratchford N, Dai H. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano. 2007;1:50-56.
38. Murakami T, Ajima K, Miyawaki J, Yudasaka M, Iijima S, Shiba K. Drug-loaded carbon nanohorns: adsorption and release of dexamethasone in vitro. Mol Pharm. 2004;1:399-405.
39. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-760.
40. Hu Z, Zhang C, Huang Y, Sun S, Guan W, Yao Y. Photodynamic anticancer activities of water-soluble C(60) derivatives and their biological consequences in a HeLa cell line. Chem Biol Interact. 2012;195:86-94.
41. Noori S, Hassan ZM. Tehranolide inhibits proliferation of MCF-7 human breast cancer cells by inducing G0/G1 arrest and apoptosis. Free Radic Biol Med. 2012;52:1987-1999.
42. Chong HZ, Rahmat A, Yeap SK, et al. In vitro cytotoxicity of Strobilanthes crispus ethanol extract on hormone dependent human breast adenocarcinoma MCF-7 cell. BMC Complement Altern Med. 2012;12:1-10.